These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 30565407)

  • 1. BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study.
    Heise T; Meiffren G; Alluis B; Seroussi C; Ranson A; Arrubla J; Correia J; Gaudier M; Soula O; Soula R; DeVries JH; Klein O; Bode B
    Diabetes Obes Metab; 2019 Apr; 21(4):1066-1070. PubMed ID: 30565407
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial.
    Heise T; Zijlstra E; Nosek L; Rikte T; Haahr H
    Diabetes Obes Metab; 2017 Feb; 19(2):208-215. PubMed ID: 27709762
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14-day crossover treatment study in people with type 1 diabetes.
    Andersen G; Meiffren G; Lamers D; DeVries JH; Ranson A; Seroussi C; Alluis B; Gaudier M; Soula O; Heise T
    Diabetes Obes Metab; 2018 Nov; 20(11):2627-2632. PubMed ID: 29923294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.
    Heise T; Hövelmann U; Brøndsted L; Adrian CL; Nosek L; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):682-8. PubMed ID: 25846340
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus.
    Haahr H; Pieber TR; Mathieu C; Gondolf T; Shiramoto M; Erichsen L; Heise T
    Clin Pharmacokinet; 2019 May; 58(5):639-649. PubMed ID: 30402720
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Comparison of Pharmacokinetic and Pharmacodynamic Properties Between Faster-Acting Insulin Aspart and Insulin Aspart in Elderly Subjects with Type 1 Diabetes Mellitus.
    Heise T; Hövelmann U; Zijlstra E; Stender-Petersen K; Jacobsen JB; Haahr H
    Drugs Aging; 2017 Jan; 34(1):29-38. PubMed ID: 27873152
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects.
    Haahr H; Sasaki T; Bardtrum L; Ikushima I
    J Diabetes Investig; 2016 Jul; 7(4):574-80. PubMed ID: 27181070
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic and Pharmacodynamic Properties of Faster-Acting Insulin Aspart versus Insulin Aspart Across a Clinically Relevant Dose Range in Subjects with Type 1 Diabetes Mellitus.
    Heise T; Stender-Petersen K; Hövelmann U; Jacobsen JB; Nosek L; Zijlstra E; Haahr H
    Clin Pharmacokinet; 2017 Jun; 56(6):649-660. PubMed ID: 27878566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
    Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
    Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose clamp, crossover study.
    Heise T; Eckers U; Kanc K; Nielsen JN; Nosek L
    Diabetes Technol Ther; 2008 Dec; 10(6):479-85. PubMed ID: 19049377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-Dose Euglycemic Clamp Study Demonstrating Pharmacokinetic and Pharmacodynamic Similarity Between SAR341402 Insulin Aspart and US- and EU-Approved Versions of Insulin Aspart in Subjects with Type 1 Diabetes.
    Kapitza C; Nosek L; Schmider W; Teichert L; Nowotny I
    Diabetes Technol Ther; 2020 Apr; 22(4):278-284. PubMed ID: 31825248
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmacokinetics and pharmacodynamics of different modes of insulin pump delivery. A randomized, controlled study comparing subcutaneous and intravenous administration of insulin aspart.
    Ihlo CA; Lauritzen T; Sturis J; Skyggebjerg O; Christiansen JS; Laursen T
    Diabet Med; 2011 Feb; 28(2):230-6. PubMed ID: 21219436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better postprandial glucose stability during continuous subcutaneous infusion with insulin aspart compared with insulin lispro in patients with type 1 diabetes.
    Bartolo PD; Pellicano F; Scaramuzza A; Sardu C; Casetti T; Bosi E; Miselli V; Brandolini S; Fabbri T; Meandri P; Cannatà F
    Diabetes Technol Ther; 2008 Dec; 10(6):495-8. PubMed ID: 19049379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
    Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
    Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device.
    Landau Z; Klonoff D; Nayberg I; Feldman D; Levit SB; Lender D; Mosenzon O; Raz I; Wainstein J
    Diabetes Metab Res Rev; 2014 Nov; 30(8):686-92. PubMed ID: 24610683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
    Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
    Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glycemic control after 6 days of insulin pump reservoir use in type 1 diabetes: results of double-blind and open-label cross-over trials of insulin lispro and insulin aspart.
    Tamborlane WV; Renard E; Wadwa RP; Blevins T; Jacober SJ; Liu R; D'Souza DN; Rees TM
    J Diabetes; 2015 Mar; 7(2):270-8. PubMed ID: 24734891
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart.
    Shiramoto M; Nishida T; Hansen AK; Haahr H
    J Diabetes Investig; 2018 Mar; 9(2):303-310. PubMed ID: 28556616
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
    Pieber TR; Svehlikova E; Brunner M; Halberg IB; Due Thomsen KM; Haahr H
    Diabetes Obes Metab; 2019 Sep; 21(9):2068-2075. PubMed ID: 31069935
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.